No dominant structural financial risk is present; the primary risks for existing shareholders are pipeline execution and patent cliff exposure — specifically, the company's dependence on a concentrated set of blockbuster products facing loss of exclusivity, the execution challenge of replacing that revenue through in-house R&D and acquired IPRD investments, and ongoing pricing pressure from U.S. drug pricing reform — none of which constitute an acute structural threat given $10.2 billion in cash and strong operating revenue, but each of which could materially affect the long-term earnings trajectory.
📉
Common Outcome:Sideways drift likely
⚠️
Secondary Risk:Elevated structural risks
🎯
Confidence:MODERATE
All risk signals are derived directly from SEC filings and supported by cited financial disclosures — not opinion or speculation.
BMY Stock Risk Analysis
BMY is a NYSE-listed stock with lower risk characteristics — a DredgeCap risk score of 3.8/10. No dominant structural financial risk is flagged in the most recent SEC filings; the primary considerations for existing shareholders are discussed in the analysis below, with supporting financial detail drawn from the 10-K and 10-Q.
Company Overview
Bristol-Myers Squibb Company is a global biopharmaceutical company incorporated in Delaware, engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines for serious diseases including oncology, hematology, immunology, cardiovascular, and neuroscience. The company operates as a single reportable segment and competes with global research-based drug companies, smaller research firms, and generic manufacturers. BMS's common stock and multiple series of fixed-rate senior notes are listed on the New York Stock Exchange.
AI-generated summary based on SEC filings. May contain errors. See disclosure
Investment Risk Score
NEUTRAL
3.8/10
MODERATE RISK
Dilution Risk
LOW2.0/10
Liquidity Risk
LOW2.5/10
Debt Toxicity
MODERATE4.5/10
Profitability Risk
MODERATE4.0/10
Premium Report
Full BMY Stock Risk Report
The integrated analysis — primary risk driver in plain language, expected shareholder outcome, what would materially change the view, and what moves the stock. One-time $7.99, lifetime access for BMY.
BMY Risk Summary
⬤
Going Concern
No going concern warning
⬤
Accumulated Deficit
Not present in the provided source material; retained earnings figure not separately isolable from the equity section excerpts provided, though the equity table references a retained earnings component as of December 31, 2023 of $28,766 million (prior period).
⬤
Revenue
Flat
⬤
Dilution
Share repurchases of $5,306 million in treasury stock are reflected in the 2023 equity table, indicating the company has historically been a net repurchaser of shares rather than a net issuer; no evidence of material share issuance or dilutive equity financing is present in the provided source material. — A small convertible debt line item ($4 million in additional paid-in capital and $11 million in retained earnings impact in 2023) is referenced in the equity table, but conversion terms, outstanding principal, and dilutive mechanics are not present in the provided source material; this does not appear to be a material dilution exposure based on the scale of the figures. No ATM facility, warrant overhang, or discounted convertible structure is evidenced in the provided excerpts.
Conclusion
Bristol-Myers Squibb is a large, diversified pharmaceutical company generating approximately $47–48 billion in annual revenue with $10.2 billion in cash and equivalents as of December 31, 2025, a conventional fixed-rate debt structure, and no auditor going concern warning in the provided source material. The primary risk for existing shareholders is not financial structure — which is…
Premium Report
Unlock the full BMY report
Plain-English dilution, debt, going-concern, and financials — every claim cited to a filing. One-time $7.99, lifetime access.